|
|
Office Locations:
|
320 Bent Street, 4th Floor
Cambridge, MA 02141
| | |
|
|
|
|
|
Life Sciences & Healthcare
|
|
|
|
MRL Ventures Fund is a corporate venture fund for Merck, and is actively developing a portfolio of early-stage therapeutic companies, which are focused on delivering innovative therapies to improve patient care. The fund does not invest in medical devices, diagnostic platforms or digital health. MRL makes seed and early-stage company investments, and seeks to invest up to $15 million per company, providing long-term, and committed capital. MRL will lead or join a syndicate of investors and play an active role on company boards. MRL invests globally and does not ask for any product or technology rights as a condition of investment. The fund has deployed almost $90 million.
|
|
|
|
|
Investment Firm Key
VC = Venture Capital
PE = Private Equity
A = Angel
I = Incubator
MB = Merchant Bank
VD = Venture Debt
FI = Family Investment Office
FOF = Fund of Funds
ED = Economic Development Office
TT = Technology Transfer Office
CVC = Corporate Venture Capital
SEC = Secondary Purchaser
HF = Hedge Fund/Mutual Fund
|
|
| COMPANY STAGE | REVENUE |
| Venture Capital | |
Seed Stage
(includes "pre-seed," or
concept stage) | No Revenue |
| Early Stage | Minimal
Revenue |
Growth Stage
(also called Mid-stage) | $2M-$7M |
Expansion Stage
(also called Late-stage) | $7M and greater |
| Private Equity | |
| Lower Middle Market | $10M-$249M |
| Middle Market | $250M-$499M |
| Upper Middle Market | $500M-$1B |
| Large Cap | >$1B |
|
|
|
|
|
